Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1996 3
1997 3
1998 11
1999 6
2000 6
2001 7
2002 6
2003 6
2004 6
2005 14
2006 11
2007 10
2008 11
2009 10
2010 14
2011 12
2012 15
2013 18
2014 17
2015 10
2016 15
2017 18
2018 22
2019 24
2020 15
2021 17
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

291 results
Results by year
Filters applied: . Clear all
Page 1
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators. Fellström BC, et al. Among authors: de fijter jw. Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28. Lancet. 2017. PMID: 28363480 Clinical Trial.
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Pascual J, et al. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11. J Am Soc Nephrol. 2018. PMID: 29752413 Free PMC article. Clinical Trial.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
Reinwald M, Silva JT, Mueller NJ, Fortún J, Garzoni C, de Fijter JW, Fernández-Ruiz M, Grossi P, Aguado JM. Reinwald M, et al. Among authors: de fijter jw. Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S53-S70. doi: 10.1016/j.cmi.2018.02.009. Epub 2018 Feb 16. Clin Microbiol Infect. 2018. PMID: 29454849 Free article. Review.
Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J; TRANSFORM investigators. Berger SP, et al. Among authors: de fijter jw. Am J Transplant. 2019 Nov;19(11):3018-3034. doi: 10.1111/ajt.15480. Epub 2019 Jul 1. Am J Transplant. 2019. PMID: 31152476 Free article. Clinical Trial.
Sirolimus and everolimus in kidney transplantation.
Moes DJ, Guchelaar HJ, de Fijter JW. Moes DJ, et al. Among authors: de fijter jw. Drug Discov Today. 2015 Oct;20(10):1243-9. doi: 10.1016/j.drudis.2015.05.006. Epub 2015 Jun 4. Drug Discov Today. 2015. PMID: 26050578 Review.
Transplanting the elderly: Balancing aging with histocompatibility.
Dreyer GJ, Hemke AC, Reinders ME, de Fijter JW. Dreyer GJ, et al. Among authors: de fijter jw. Transplant Rev (Orlando). 2015 Oct;29(4):205-11. doi: 10.1016/j.trre.2015.08.003. Epub 2015 Sep 2. Transplant Rev (Orlando). 2015. PMID: 26411382 Review.
291 results